MA27934A1 - Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres - Google Patents

Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres

Info

Publication number: MA27934A1
Authority: MA; Morocco
Prior art keywords: fluoro; pyrrolidinecarbonitrile; phenylalanyl; fluorophenyl; beta
Prior art date: 2003-07-21

Application number

MA28758A

Other languages

English (en)

Inventor

Igo H David

Johnson R Paul

Patterson E Daniel

Sab Randhawa Amarjit

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-21

Filing date

2006-01-27

Publication date

2006-06-01

2006-01-27 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2006-06-01 Publication of MA27934A1 publication Critical patent/MA27934A1/fr

Links

JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title 2
-1 4-FLUOROPHENYL Chemical class 0.000 title 1
MSCWUTTUQLYJFT-QMBKNIKNSA-N (2s,4s)-1-[(2s)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 MSCWUTTUQLYJFT-QMBKNIKNSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)

MA28758A 2003-07-21 2006-01-27 Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres MA27934A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US48890203P	2003-07-21	2003-07-21

Publications (1)

Publication Number	Publication Date
MA27934A1 true MA27934A1 (fr)	2006-06-01

Family

ID=34102801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA28758A MA27934A1 (fr)	2003-07-21	2006-01-27	Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres

Country Status (17)

Country	Link
US (1)	US7462641B2 (fr)
EP (1)	EP1654226B1 (fr)
JP (1)	JP2006528187A (fr)
KR (1)	KR20060037391A (fr)
CN (1)	CN1852893A (fr)
AT (1)	ATE411980T1 (fr)
AU (1)	AU2004259741A1 (fr)
BR (1)	BRPI0412763A (fr)
CA (1)	CA2532397A1 (fr)
DE (1)	DE602004017325D1 (fr)
IL (1)	IL173059A0 (fr)
MA (1)	MA27934A1 (fr)
MX (1)	MXPA06000725A (fr)
NO (1)	NO20060399L (fr)
RU (1)	RU2006106429A (fr)
WO (1)	WO2005009956A1 (fr)
ZA (1)	ZA200600605B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1753748T3 (pl)	2004-05-12	2010-01-29	Pfizer Prod Inc	Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
KR20080000665A (ko)	2005-04-22	2008-01-02	알란토스 파마슈티컬즈 홀딩, 인코포레이티드	디펩티딜 펩티다아제-ⅳ 억제제
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CN101641153B (zh)	2007-04-05	2012-08-15	株式会社日本触媒	以吸水性树脂为主成分的粒子状吸水剂
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
KR101653548B1 (ko) *	2008-01-08	2016-09-02	머크 샤프 앤드 돔 리미티드	2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
AU2009223701B2 (en) *	2008-03-12	2015-04-16	Intra-Cellular Therapies, Inc.	Substituted heterocycle fused gamma-carbolines solid
EP2108960A1 (fr)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
EP2348857B1 (fr)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
US8329914B2 (en)	2008-10-31	2012-12-11	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP5685550B2 (ja)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2795513A1 (fr)	2010-04-06	2011-10-13	Arena Pharmaceuticals, Inc.	Modulateurs du recepteur de gpr119 et traitement de troubles associes
EP3323818A1 (fr)	2010-09-22	2018-05-23	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
SG192941A1 (en)	2011-02-25	2013-09-30	Merck Sharp & Dohme	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (fr)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
KR20140146192A (ko)	2012-04-14	2014-12-24	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
WO2014074668A1 (fr)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
KR20150118158A (ko)	2013-02-22	2015-10-21	머크 샤프 앤드 돔 코포레이션	항당뇨병 비시클릭 화합물
WO2014139388A1 (fr)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
US9708322B2 (en)	2013-03-15	2017-07-18	Intra-Cellular Therapies, Inc.	Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
WO2015051496A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Composés tricycliques antidiabétiques
KR102373288B1 (ko)	2013-12-03	2022-03-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 방법
CA2944755A1 (fr)	2014-04-04	2015-10-08	Intra-Cellular Therapies, Inc.	Composes organiques
US10077267B2 (en)	2014-04-04	2018-09-18	Intra-Cellular Therapies, Inc.	Organic compounds
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
PL3838274T3 (pl)	2016-01-26	2024-04-02	Intra-Cellular Therapies, Inc.	Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da)	2016-03-25	2021-08-09	Intra Cellular Therapies Inc	Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
EP3436455A4 (fr)	2016-03-28	2019-09-04	Intra-Cellular Therapies, Inc.	Nouveaux sels et cristaux
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
US11014925B2 (en)	2016-03-28	2021-05-25	Intra-Cellular Therapies, Inc.	Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3525763B1 (fr)	2016-10-12	2025-03-05	Intra-Cellular Therapies, Inc.	Dispersions solides amorphes
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298B1 (fr)	2016-12-20	2026-03-11	Merck Sharp & Dohme LLC	Composés de spirochromane antidiabétiques
WO2018126140A1 (fr)	2016-12-29	2018-07-05	Intra-Cellular Therapies, Inc.	Composés organiques
EP3562484B1 (fr)	2016-12-29	2021-08-25	Intra-Cellular Therapies, Inc.	Dérivés de pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline utiles dans les traitements de troubles du snc
RU2767410C2 (ru)	2017-03-24	2022-03-17	Интра-Селлулар Терапиз, Инк.	Новые композиции и способы
JP2020515639A (ja)	2017-04-03	2020-05-28	コヒラス・バイオサイエンシズ・インコーポレイテッド	進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
EP3658144B1 (fr)	2017-07-26	2022-01-26	Intra-Cellular Therapies, Inc.	Composés pyridopyrroloquinoxalines, leurs compositions et utilisations en thérapie
WO2019023062A1 (fr)	2017-07-26	2019-01-31	Intra-Cellular Therapies, Inc.	Composés organiques
US11440911B2 (en)	2017-09-26	2022-09-13	Intra-Cellular Therapies, Inc.	Salts and crystals
CN109867674A (zh) *	2017-12-05	2019-06-11	上海度德医药科技有限公司	一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
CN112040940A (zh)	2018-03-23	2020-12-04	细胞内治疗公司	有机化合物
AU2019280850C1 (en)	2018-06-06	2025-02-13	Intra-Cellular Therapies, Inc.	Novel salts and crystals
EP3801527B1 (fr)	2018-06-08	2025-02-19	Intra-Cellular Therapies, Inc.	Gamma-carbolines fusionnées pour le traitement aigu de l'anxiété ou de la dépression
CA3240552A1 (fr)	2018-06-11	2019-12-19	Intra-Cellular Therapies, Inc.	Synthese de gamma-carbolines fusionnees a heterocycles substitues
US12144808B2 (en)	2018-08-29	2024-11-19	Intra-Cellular Therapies, Inc.	Compositions and methods
WO2020047408A1 (fr)	2018-08-31	2020-03-05	Intra-Cellular Therapies, Inc.	Nouvelles méthodes
BR112021003655A2 (pt)	2018-08-31	2021-05-18	Intra-Cellular Therapies, Inc.	métodos novos
JP2022504228A (ja)	2018-10-03	2022-01-13	テサロ，インコーポレイテッド	ニラパリブ遊離塩基の結晶形態
WO2021007245A1 (fr)	2019-07-07	2021-01-14	Intra-Cellular Therapies, Inc.	Nouveaux procédés
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1723196A (zh) *	2001-06-27	2006-01-18	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷

2004
- 2004-07-19 AT AT04778669T patent/ATE411980T1/de not_active IP Right Cessation
- 2004-07-19 DE DE602004017325T patent/DE602004017325D1/de not_active Expired - Fee Related
- 2004-07-19 BR BRPI0412763-3A patent/BRPI0412763A/pt not_active Application Discontinuation
- 2004-07-19 US US10/565,294 patent/US7462641B2/en not_active Expired - Fee Related
- 2004-07-19 WO PCT/US2004/023263 patent/WO2005009956A1/fr not_active Ceased
- 2004-07-19 CN CNA2004800270931A patent/CN1852893A/zh active Pending
- 2004-07-19 JP JP2006521180A patent/JP2006528187A/ja active Pending
- 2004-07-19 EP EP04778669A patent/EP1654226B1/fr not_active Expired - Lifetime
- 2004-07-19 KR KR1020067001464A patent/KR20060037391A/ko not_active Ceased
- 2004-07-19 MX MXPA06000725A patent/MXPA06000725A/es unknown
- 2004-07-19 RU RU2006106429/04A patent/RU2006106429A/ru not_active Application Discontinuation
- 2004-07-19 CA CA002532397A patent/CA2532397A1/fr not_active Abandoned
- 2004-07-19 AU AU2004259741A patent/AU2004259741A1/en not_active Abandoned
2006
- 2006-01-10 IL IL173059A patent/IL173059A0/en unknown
- 2006-01-20 ZA ZA200600605A patent/ZA200600605B/en unknown
- 2006-01-25 NO NO20060399A patent/NO20060399L/no not_active Application Discontinuation
- 2006-01-27 MA MA28758A patent/MA27934A1/fr unknown

Also Published As

Publication number	Publication date
DE602004017325D1 (de)	2008-12-04
EP1654226B1 (fr)	2008-10-22
WO2005009956A1 (fr)	2005-02-03
MXPA06000725A (es)	2006-03-30
IL173059A0 (en)	2006-06-11
US20070066677A1 (en)	2007-03-22
CN1852893A (zh)	2006-10-25
NO20060399L (no)	2006-02-17
JP2006528187A (ja)	2006-12-14
AU2004259741A1 (en)	2005-02-03
KR20060037391A (ko)	2006-05-03
BRPI0412763A (pt)	2006-09-26
US7462641B2 (en)	2008-12-09
RU2006106429A (ru)	2006-08-27
ATE411980T1 (de)	2008-11-15
CA2532397A1 (fr)	2005-02-03
EP1654226A1 (fr)	2006-05-10
ZA200600605B (en)	2007-05-30

Publication	Publication Date	Title
MA27934A1 (fr)	2006-06-01	Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres
EA200400026A1 (ru)	2004-04-29	Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтические применения и вещества для их синтеза
EA200301289A1 (ru)	2004-06-24	Новые производные пиррола в качестве фармацевтических средств
DK1712547T3 (da)	2012-03-19	Bicycloesterderivat
IT1235048B (it)	1992-06-17	Derivato di 4h-benzopiran-4-one o suo sale, procedimento per produrlo e composizione farmaceutica che lo contiene come ingrediente attivo
SV2003001144A (es)	2003-03-18	FORMAS CRISTALINAS DE LA SAL DE CALCIO DEL ACIDO [R-(R,R)]-2-(4-FLUOROFENIL)-ß,ô-DIHIDROXI-5-(1-METILETIL)-3-FENIL-4[(FENILAMINO)CARBONIL]-1H-PIRROL-1-HEPTANOICO (2:1) REF. PC430-01FJT
DK0528858T3 (da)	1997-07-28	Inhibitorer af dipeptidyl-aminopeptidase type IV
BG101284A (bg)	1998-03-31	Съединения и методи за лечение на рак
BR0113161A (pt)	2004-04-06	Arilóxi piperidinas não imidazóis
ATE267830T1 (de)	2004-06-15	Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
DE69719755D1 (de)	2003-04-17	Polymorphe verbindungen
ES2171723T3 (es)	2002-09-16	3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EE200300168A (et)	2003-06-16	Tripeptidüülpeptidaasi inhibiitorid, nende valmistamine ja kasutamine ravimina ning neid sisaldav farmatseutiline kompositsioon
DK1309562T3 (da)	2008-08-11	4-Alkoxycyclohexan-1-aminocarboxylsyreestere og fremgangsmåde til fremstilling deraf
EA200100807A1 (ru)	2002-08-29	Производные алкинилсодержащих гидроксамовых кислот и их применение в качестве ингибиторов tace
EA200300579A1 (ru)	2003-12-25	Соединение лактама
DE69632876D1 (de)	2004-08-12	2-Amino-Benzoxazinone zur Behandlung von viralen Infektionen
ES2195033T3 (es)	2003-12-01	Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
ATE280776T1 (de)	2004-11-15	Medizinische verwendung von mechanismus- orientierten inhibitoren der dipeptidylpeptidase i
ES2076838T3 (es)	1995-11-01	Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.
EA200400751A1 (ru)	2004-12-30	Применение дезоксипеганина для лечения клинической депрессии
GEP20063936B (en)	2006-10-10	New anhydrous crystalline forms of gabapentin
DK1178985T3 (da)	2003-07-28	Substituerede thienocycloalk(en)ylamino-1,3,5-triaziner
PT1244614E (pt)	2004-10-29	Inibidores de triptase